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Havel, Peter J., Thomas 0. Mundinger, Richard C. 
Veith, Beth E. Dunning, and Gerald J. Taborsky, Jr. 
Corelease of galanin and NE from pancreatic sympathetic 
nerves during severe hypoglycemia in dogs. Am. J. Physiol. 263 
(Elzdocrinol. Metab. 26): E&E16,1992.-To determine whether 
norepinephrine (NE) and galanin are coreleased during reflex 
activation of the sympathetic nervous system by hypoglycemia, 
we administered insulin to halothane-anesthetized (0.8%) dogs 
and measured the spillover of NE and galanin-like immunore- 
activity (GLIR) into pancreatic venous plasma. Insulin injec- 
tion produced hypoglycemia [plasma glucose (PG) = 34 t 3 
mg/dl] but did not activate pancreatic noradrenergic (Apancre- 
atic NE output = +20 ,t 130 pg/min) or galaninergic nerves 
(AGLIR output = +40 t 50 fmol/min). To determine whether 
more severe hypoglycemia would activate these nerves, insulin 
was administered to dogs infused with somatostatin (SS; 2.5 
pg/min) to block the counterregulatory increase of glucagon 
secretion. SS reduced the glucagon response to hypoglycemia by 
>90%, which allowed PG to decrease to 14 t 1 mg/dl. Pancre- 
atic NE output increased by 470 t 140 pg/min (P < 0.005); 
however, pancreatic GLIR output did not increase significantly 
(A = +70 k 50 fmol/min). When SS was discontinued, pancre- 
atic NE output increased by 490 t 200 pg/min (P < 0.025), and 
GLIR output increased by an additional +160 t 70 fmol/min 
(P < 0.025; total A from baseline = +230 t 90 fmol/min, 
P < 0.025), suggesting that SS may restrain pancreatic NE and 
galanin release. Pancreatic NE and GLIR spillover were also 
increased during severe hypoglycemia when ganglionic neu- 
rotransmission was partially impaired with hexamethonium but 
not when the neural pathway was interrupted by spinal cord 
transection. We conclude that NE and galanin are coreleased 
from pancreatic sympathetic nerves when these nerves are 
centrally activated during severe hypoglycemia in halothane- 
anesthetized dogs. 
norepinephrine; neuropeptide; somatostatin; glucagon; hexa- 
methonium; halothane anesthesia; spinal cord transection; neu- 
roglucopenia; stress; catecholamines 
IT IS WELL ESTABLISHED that sympathetic nerves in- 
nervating the pancreatic islets contain and release the 
classic neurotransmitter norepinephrine (NE) (2 1, 30). 
However, recent evidence suggests that the peptide gala- 
nin may also be a sympathetic neurotransmitter in the 
canine pancreas (22). First, galanin-like immunoreactiv- 
ity (GLIR) is present in sympathetic nerves innervating 
pancreatic islets (1, 38, 46). Second, the administration 
of synthetic galanin qualitatively reproduces the 
changes of pancreatic islet hormone secretion observed 
during electrical sympathetic nerve stimulation (19, 42, 
50, 52), whereas the administration of NE alone is not 
sufficient to mediate these changes of islet hormone 
secretion in dogs (5, 20). Finally, the amount of 
GLIR released during intense electrical stimulation 
of sympathetic nerves appears sufficient to mediate the 
observed impairment of insulin secretion (23). Despite 
the evidence cited above, there has been no previous 
demonstration that galanin is in fact coreleased with NE 
during the presumably less intense reflex activation of 
pancreatic sympathetic nerves that occurs during sys- 
temic stress (30). Such a demonstration would add sup- 
port to the hypothesis that galanin is a sympathetic 
coneurotransmitter in the canine pancreas. 
Studies of another putative sympathetic neuropeptide 
that is released by sympathetic nerve stimulation (6, 11, 
5l), neuropeptide Y (NPY), suggest that neuropeptides 
may not always be coreleased with classic neurotrans- 
mitters, particularly at low neuronal firing rates. Thus 
low frequencies of electrical stimulation of sympathetic 
nerves innervating porcine spleen or moderate exercise 
in humans both produce little NPY release (39, 45), 
despite significant NE release. Likewise, continuous 
electrical stimulation of the splanchnic nerves in calves 
results in much less NPY release than does burst stim- 
ulation of the same average frequency (10). There is 
apparent morphological support for these findings, in 
that NPY is contained in the large dense granules of 
sympathetic nerves and not in the small vesicles that 
also contain NE (7,18). The implication is that the large 
granules are recruited for release predominately during 
intense neural activation. Thus, if galanin is a sympa- 
thetic neuropeptide like NPY, it might not be coreleased 
with NE during the reflex activation of the pancreatic 
sympathetic nerves that occurs during neuroglucopenic 
stress (30). 
Therefore, to determine whether NE and GLIR are 
coreleased from the sympathetic nerves of the pancreas 
during stress, we measured pancreatic NE and GLIR 
output (spillover) via an extracorporeal pancreatic 
venous-portal vein shunt during two grades of insulin- 
induced hypoglycemia in acute terminal experiments 
performed in halothane-anesthetized laparotomized 
dogs. In one group of dogs, insulin was administered by 
itself, resulting in hypoglycemia with a glucose level of 
-35 mg/dl. In a second experiment, insulin was admin- 
istered to another group of dogs, in which somatostatin 
(SS) was infused to inhibit the counterregulatory gluca- 
gon response, and thus more severe hypoglycemia was 
produced ( 5 15 mg/dl). 
An additional experiment was performed to confirm 
that increased pancreatic NE and GLIR responses occur 
during severe hypoglycemia. In this experiment, severe 
hypoglycemia was produced by partially blocking hy- 
poglycemia-induced autonomic activation, which, in the 
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dog, is a major determinant of the glucagon response 
(31); therefore the glucose nadir after insulin injection is 
lowered. The autonomic response was reduced by 
administration of the ganglionic blocking agent 
hexamethonium. Because the dose employed was sub- 
maximal by design, this intervention still allowed acti- 
vation of pancreatic sympathetic nerves in response to 
hypoglycemia. 
Last, to determine whether increased NE and galanin 
output resulted from a central reflex that activates pan- 
creatic sympathetic nerves (30) or was possibly due to a 
local effect of severe hypoglycemia on pancreatic sym- 
pathetic nerve terminals (15, 35), we produced equiva- 
lent severe hypoglycemia in dogs, in which the sympa- 
thetic neural pathway was surgically interrupted at the 
level of the cervical spinal cord. 
METHODS 
Animals and pancreatic preparation. After an overnight fast 
(h* 18 h), adult dogs of mixed breed (24-40 kg) were anesthetized 
with the ultrashort-acting barbiturate thiamylal sodium (Suri- 
tal; Parke Davis, Morris Plains, NJ). Anesthesia was subse- 
quently maintained with halothane (0.8%) administered from a 
calibrated vaporizer (Draeger, FRG) by mechanical ventilation 
in 100% oxygen. This anesthetic regimen was chosen because it 
has been shown to provide full surgical anesthesia but does 
not suppress parasympathetic or sympathoadrenal activation 
induced by the neuroglucopenic agent 2-deoxy-D-glucose 
(28, 29) as do some other anesthetics, e.g., pentobarbital 
sodium (53, 54). 
To access pancreatic venous blood, a laparotomy was per- 
formed, and an extracorporeal Silastic (Dow Corning, Midland, 
MI) shunt containing a sampling port, an electromagnetic flow 
probe (In Vivo Metric Systems, Healdsburg, CA), and a heparin 
infusion line were placed between the superior pancreati- 
coduodenal vein (SPDV) and the portal vein (5). This procedure 
allows the measurement of hormone output and neurotransmit- 
ter spillover from the right lobe (duodenal lobe and uncinate 
process) of the canine pancreas (-35-50% of the pancreas). 
This preparation also receives a portion of the venous drainage 
from the proximal duodenum. To minimize the duodenal con- 
tribution to SPDV blood, the main duodenal input to the SPDV 
was isolated and ligated between the pancreas and duodenum. 
The femoral artery (FA) and vein were cannulated for blood 
sampling and drug infusion, respectively. Saline (0.9%) was in- 
fused intravenously at a slow rate throughout the surgery and 
the experiments. 
All surgery and experiments were performed in the presence 
of full surgical anesthesia. These experiments were acute termi- 
nal procedures. At the conclusion of each day’s experimental 
protocol, each animal used in these studies was killed with an 
overdose of barbiturate anesthetic, thiopental sodium (Pen- 
tothal; Abbott Laboratories, North Chicago, IL), without re- 
gaining consciousness. 
Hypoglycemia protocol. To determine whether hypoglycemia 
would produce central reflex activation of pancreatic noradren- 
ergic and galaninergic nerves, insulin was administered to four 
groups of animals as follows: control, SS-infused, hexametho- 
nium-treated, and cord-sectioned dogs. One hour after the sur- 
gical procedures, paired arterial and pancreatic venous blood 
samples for glucose, glucagon, catecholamine, and galanin de- 
termination were drawn from the FA and from the pancreatic 
venous shunt at -10 and 0 min before insulin injection to es- 
tablish baseline values for the subsequent experiments. To pro- 
duce acute marked hypoglycemia in control dogs, a bolus of 
regular porcine insulin (Squibb-Novo, Bagsvaerd, Denmark) 
was administered into the femoral vein cannula at a dose of 
5.0 + 1.4 U/kg (range 1.2-12.0 U/kg). Doses were chosen to 
decrease plasma glucose to ~40 mg/dl in all control dogs. The 
SS-infused dogs received 3.7 & 1.2 U/kg of insulin (range 
1.2-12.0 U/kg). Hexamethonium-treated dogs or cord-sectioned 
dogs received less insulin (0.6 U/kg) because, in these animals, 
lower doses were required to produce decrements of plasma 
glucose that were larger than those in the control dogs. Plasma 
glucose fell below 25 mg/dl in all SS-infused, hexamethonium- 
treated, and cord-sectioned dogs. Paired arterial and pancreatic 
venous blood samples were drawn at 5,15,30,35,40,45,50,55, 
and 60 min after insulin injection. After 60 min, the hypogly- 
cemia was reversed by administering glucose (50% solution) 
intravenously as a bolus of 200 mg/kg followed by an infusion of 
lo-20 mg. kg-l l min-’ to equal or exceed baseline arterial glu- 
cose levels for 30 min. Paired samples were drawn at 5, 15, and 
30 min after the start of the glucose infusion. In all experiments, 
blood flow in the pancreatic venous shunt was monitored with 
an electromagnetic flowmeter (Zepeda Instruments, Seattle, 
WA). Hematocrit was determined at regular intervals through- 
out the experiments. 
SS infusion study. To lower the plasma glucose further than 
in the control dogs, the counterregulatory glucagon response to 
hypoglycemia was prevented in 11 experiments by infusing syn- 
thetic cyclic SS-14 (Bachem, Torrance, CA) intravenously at a 
rate of 2.5 pg/min. 
The hypoglycemia protocol in the SS-infused dogs differed 
somewhat from the protocol in the other three groups. Two 
pre-SS samples were drawn at 1 h postsurgery, after which SS 
was infused for 20 min before the injection of insulin and con- 
tinued until 60 min after the insulin injection. Samples were 
drawn at 5,10, and 20 min into the SS infusion and at 5,15,30, 
45, 50, 55, and 60 min postinsulin. The SS infusion was then 
discontinued, and three additional samples were drawn at 65, 
70, and 75 min postinsulin, after which glucose was infused for 
30 min to reverse the hypoglycemia as in the other experimental 
protocols. 
Hexamethonium experiment. To produce severe hypoglyce- 
mia by a second independent method, a submaximal dose of the 
ganglionic blocking agent hexamethonium was administered be- 
fore the injection of insulin. Hexamethonium impairs neu- 
rotransmission across autonomic ganglia and the adrenal me- 
dulla by interfering with postsynaptic signaling via nicotinic 
receptors (56). Previous data had demonstrated that this dose 
of hexamethonium substantially diminished hypoglycemia- 
induced autonomic activation and thereby markedly impaired 
glucagon responses to hypoglycemia, resulting in a lower glucose 
nadir after insulin injection (~15 mg/dl) (31). However, this 
dose of hexamethonium still allows a significant degree of sym- 
pathetic nervous system activation during hypoglycemia, as re- 
flected by an increase of arterial plasma NE levels (31). Hex- 
amethonium bromide (Sigma Chemical, St. Louis, MO) was 
administered intravenously (20-30 min before baseline samples 
were drawn) in increments until arterial blood pressure was 
clearly decreased in each animal. Each dog was given repetitive 
0.1 mg/kg doses until the blood pressure was decreased by at 
least 10 mmHg, 90 s after the injection. After the bolus injec- 
tions, an increment of 0.7 pg* kg-l emin-‘, for each 0.1 mg/kg 
administered initially, was infused continuously throughout the 
experiments (3). Consequently, the dose of hexamethonium 
was variable and ranged from 0.2 to 0.5 mg/kg plus 1.4 to 
3.5 hgm kg-’ emin-‘. 
Surgical interruption of sympathetic outflow. To determine 
whether the increased release of pancreatic NE and GLIR was 
due to a centrally mediated reflex activation of the sympathetic 
outflow to the pancreas or to a local effect of low plasma glucose 
levels directly on pancreatic sympathetic nerves, cervical spinal 
cord transection was performed in six dogs. This procedure 
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interrupts the sympathetic neural pathway from the brain to 
the pancreas and adrenal medulla, impairs the counterregula- 
tory increases of glucagon and plasma catecholamines during 
hypoglycemia, and thereby allows plasma glucose to fall to ex- 
tremely low levels (31). In these animals, the cervical spinal cord 
was exposed through a dorsal midline incision by removing part 
of the spinous process and the arch of the axis. To prevent 
activation of any nociceptive reflexes, 3 ml of 2% lidocaine 
hydrochloride were injected with a Z-gauge needle directly into 
the exposed spinal cord in several locations. Five minutes later, 
2-3 cm of the cord were excised to ensure complete interruption 
of spinal efferents. Bleeding was controlled by tightly packing 
the vertebral foramen with gauze soaked in mineral oil. These 
acute terminal procedures were performed in the presence of full 
surgical anesthesia. At the conclusion of the experiments, each 
animal was killed with an overdose of anesthetic, without re- 
gaining consciousness. 
Assays. Blood samples for glucose determination were drawn 
and placed in tubes containing EDTA. Blood samples for glu- 
cagon determination were placed in tubes containing heparin 
and benzamidine hydrochloride. Blood samples for catechola- 
mine determination were placed in tubes containing ethy- 
lene glycol-bis(P-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
(EGTA) and glutathione. Blood samples for GLIR measure- 
ment were drawn and placed in tubes containing a solution of 
anticoagulants and proteolytic enzyme inhibitors (17). All sam- 
ples were kept on ice until centrifugation (2,500 revolutions/min 
for 20 min at 4°C). The plasma was then decanted and frozen at 
-20°C until assayed. 
Plasma glucose was measured by the glucose oxidase method 
with a Technicon autoanalyzer (Technicon Instrument, San 
Francisco, CA). Plasma immunoreactive glucagon was mea- 
sured radioimmunologically in unextracted plasma with an an- 
tibody that has high specificity for the COOH-terminal portion 
of the glucagon molecule (55). It has been previously demon- 
strated that extrapancreatic immunoreactive glucagon mea- 
sured with COOH-terminal-specific antisera does not increase 
during insulin-induced hypoglycemia in dogs (41, 44). Thus 
measurements of arterial glucagon made with this assay are a 
reliable index of pancreatic glucagon secretion. Plasma NE was 
measured in duplicate with a highly sensitive and specific radi- 
oenzymatic assay (24). The intra- and interassay coefficients of 
variation for the plasma catecholamine assay in this laboratory 
are 6 and 12%, respectively. GLIR was measured in unextracted 
plasma with a radioimmunoassay with a non-COOH-terminal- 
directed antibody raised against synthetic porcine galanin and 
with synthetic porcine galanin standards as previously de- 
scribed in detail (23). Because the species-variable portion of 
the molecule is apparently limited to the COOH-terminal hep- 
tapeptide (36,48), this assay detects GLIR in all species thus far 
examined. 
Calculations and data analysis. The changes in arterial 
plasma glucose and glucagon, arterial and pancreatic venous NE 
and GLIR, pancreatic vein blood flow and hematocrit (Hct), 
and pancreatic NE and GLIR output were calculated by sub- 
tracting the mean of the -lo- and 0-min preinsulin baseline 
values from the mean of the 45-, 50-, 55-, and 60-min values 
after the injection of insulin, except in the SS-infused dogs, in 
which the mean of the 50-, 55-, and 60-min samples was used. 
The changes following the discontinuation of SS infusion were 
calculated by subtracting the mean baseline values from the 
mean of the three samples drawn at 5, 10, and 15 min after the 
SS infusion was discontinued (65, 70, and 75 min postinsulin). 
Because both circulating NE (2) and galanin (23) are ex- 
tracted by the pancreas, most of the transmitter arriving via 
the arterial circulation does not appear in pancreatic venous 
plasma, and therefore simple measurements of arteriovenous 
(a-v) concentration differences will seriously underestimate 
pancreatic neurotransmitter release. To correct the a-v differ- 
ence for extraction, neurotransmitter spillover was calculated as 
follows 
[ [NE or GLIRlspnv - (arterial contribution to SPDV level) ] 
x SPDV blood flow x (1 - Hct) 
where square brackets indicate concentration. The arterial con- 
tribution to the SPDV level is defined as the amount of neu- 
rotransmitter present in SPDV plasma that arrives via the ar- 
terial circulation and escapes pancreatic extraction. Because 
epinephrine (Epi) is extracted at a rate similar to NE (2), Epi 
extraction was used as an index of NE extraction and was 
employed to calculate the arterial contribution to SPDV NE 
levels when arterial Epi levels were high. When arterial Epi 
levels were very low, such as during the baseline period before 
hypoglycemia in cord-sectioned animals, Epi extraction is not a 
reliable index of NE extraction. NE extraction during such 
baseline conditions has been measured and found to average 
75% with little variability. Therefore an extraction rate for NE 
of 75% was used to calculate NE output at time points when Epi 
levels were low. 
Thus the arterial contribution to SPDV NE levels is calcu- 
lated as 
[NEIFA x (1 - pancreatic Epi extraction or 1 - 0.75) 
pancreatic Epi extraction is calculated as 
WPilFA - [EPilSPD”mPilFA 
In the case of galanin, in the basal state, nearly all plasma 
GLIR represents a large-molecular-weight cross-reactant in the 
radioimmunoassay (23). It is present in approximately equal 
amounts in FA and SPDV plasma and thus does not appear to 
be subject to pancreatic extraction (21). Therefore only the 
increment over the basal FA level was considered to be true 
galanin and used in the extraction/spillover calculations. Pan- 
creatic extraction of infused exogenous galanin has been mea- 
sured and found to average 65% over a wide range of plasma 
galanin concentrations (23). Thus pancreatic galanin spillover 
was calculated as follows 
spillover = ([ GLIR] SPDv - [ GLIRlbasal & 
+ WWWJW,, - WWbasa~ d I 
x SPDV blood flow x (1 - Hct) 
The data are expressed as means t SE. Statistical compari- 
sons of means within a group were made with a paired t test. 
Statistical comparisons of means of different groups were made 
with a two-sample t test. For multiple comparisons between 
more than two groups, analysis of variance was performed, and 
Dunnett’s posttest was employed to determine significant 
differences. The correlation between the mean changes of NE 
and galanin output was made using linear regression analysis. 
RESULTS 
Arterial glucose, glucagon, and NE and pancreatic NE 
and GLIR output responses in control dogs. In control 
dogs (n = 9) the intravenous administration of insulin 
(5.0 t 1.4 U/kg) caused plasma glucose to decrease by 
77 + 4 mg/dl to a mean level of 34 t 3 mg/dl at 45-60 min 
posinsulin injection (Table 1). The mean nadir was 30 t 
2 mg/dl at 60 min after the insulin injection. Arterial 
plasma glucagon increased by +52 t 14 pg/ml (P < 0.005, 
Table I), and arterial plasma NE levels increased by 
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Table 1. Baseline arterial glucagon and glucose concentrations and responses during hypoglycemia 
El1 
Treatment n 
Baseline 
Arterial Glucagon, pg/ml Arterial Glucose, mg/dl 
x45-60 min A45-60 min Baseline x45-60 min 
Control dogs 
SS infused 
Hexamethonium 
Spinal cord transection 
9 27k3 80215 +52&14* 1 lOIk3 34k3 
11 25t4 3Ok4 +5*2-F 103k4 14klt 
6 32k7 37k5 +5t4t 83rt4 12t2t 
6 26t4 31s +5t7t 9Ok7 15*3t 
Values are means k SE at baseline and 45-60 min postinsulin injection; n, no. of dogs. SS, somatostatin. A, change from baseline. * P < 0.005 
vs. baseline. t P < 0.01 vs. control dogs. 
+570 t 80 pg/ml (P < 0.0005; Table 2). Both arterial 
glucagon and NE decreased toward baseline during glu- 
cose infusion (data not shown). 
Pancreatic NE output did not increase during hypogly- 
cemia (A = +20 t 130 pg/min; Fig. IA and Table 3). 
Similarly, there was no significant increase of pancreatic 
GLIR output (A = +40 t 50 fmol/min; Fig. 1B and 
Table 4). 
Arterial glucose, glucagon, and NE and pancreatic NE 
and GLIR output responses after insulin injection in dogs 
infused with SS. Arterial plasma glucose before SS infu- 
sion was 108 t 4 mg/dl (n = 11). After lo-20 min of SS 
infusion, before insulin injection, plasma glucose declined 
slightly to 103 t 4 mg/dl (A = -5 t 2 mg/dl, P < 0.025). 
After insulin injection (3.7 t 1.2 U/kg), plasma glucose 
decreased to 14 t 1 mg/dl (A = -89 t 4 mg/dl), signifi- 
cantly lower than in control dogs, (P < 0.01; Table 1). 
The nadir was 13 t 1 mg/dl at 60 min postinsulin 
injection. Plasma glucose began to increase 10 min after 
the discontinuation of the SS infusion and reached 29 t 
6 mg/dl by 15 min (A = +15 t 5 mg/dl, P < 0.01 vs. during 
SS), after which glucose was infused to equal or exceed 
baseline levels. Arterial plasma glucagon averaged 32 t 5 
pg/ml before SS infusion. Plasma glucagon decreased to 
25 t 4 pg/ml (A = -7 + 3 pg/ml, P < 0.0025) after lo-20 
min of SS infusion. SS infusion prevented >90% of the 
arterial glucagon response to hypoglycemia observed in 
the control dogs (A = +5 t 2 vs. +52 t 14 pg/ml, P < 0.01; 
Table 1). When the SS infusion was discontinued, plasma 
glucagon increased rapidly to 71 t 13 pg/ml at 15 min 
(A = +41 t 11 pg/ml, P < 0.0025; data not shown). 
During the subsequent glucose infusion, arterial plasma 
glucagon decreased to 29 t 5 pg/ml at 30 min. The arte- 
rial plasma NE response in SS-infused dogs was similar 
to that of control dogs; NE increased by +420 t 110 
pg/ml, P < 0.0025 at 50-60 min postinsulin injection 
Table 2. Baseline arterial plasma NE concentrations 
and NE responses during hypoglycemia 
Treatment 
Arterial NE, pg/ml 
n 
Baseline x45-60 min A45-60 min 
Control dogs 9 170t30 740t90 +570&80* 
SS infused 11 160t20 56OkllO +420&110* 
Hexamethonium 6 llOk40 310+7O”f +200&60*t 
Spinal cord transection 6 30+10? 3oklot 0+10-f- 
Values are means t SE at baseline and 45-60 min postinsulin 
injection. NE, norepinephrine. * P < 0.025 vs. baseline. t P c 0.05 vs. 
control dogs. 
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Fig. 1. Pancreatic output of norepinephrine (NE) and galanin-like 
immunoreactivity (GLIR) before, during, and after insulin-induced 
hypoglycemia in 9 experiments conducted in control dogs. 
(Table 2). Arterial plasma NE decreased after glucose 
infusion (data not shown). 
Pancreatic NE output increased significantly during 
hypoglycemia in SS-infused dogs, (A = +470 t 150 pg/ 
min at 50-60 min after insulin injection, P C 0.005; 
Fig. 2A and Table 3). Pancreatic NE output increased by 
an additional +490 t 200 pg/min after the SS infusion 
was discontinued (total A = +970 t 280 pg/min). Pan- 
creatic GLIR output did not increase significantly during 
the SS infusion, despite severe hypoglycemia (A = +70 t 
50 fmol/min, P < 0.05); however, pancreatic GLIR out- 
put did increase substantially after the SS infusion was 
discontinued, (A = +160 t 70 fmol/min, P < 0.025; total 
A = +230 + 90 pg/min, P < 0.025; Fig. 2B and Table 4). 
Arterial glucose, glucagon, and NE and pancreatic NE 
and GLIR responses after insulin injection in dogs pre- 
treated with hexamethonium. After insulin injection 
(0.6 t 0.1 U/kg; n = 6), in hexamethonium-treated dogs, 
plasma glucose declined to 12 t 2 mg/dl (A = -71 t 3 
mg/dl), a decrement similar to that observed in control 
dogs. The nadir of 11 t 1 mg/dl (60 min postinsulin 
injection) was significantly lower than in the control dogs 
(P c 0.0005). Arterial plasma glucagon did not increase 
significantly during hypoglycemia (A = +5 t 4 pg/ml); 
this response was significantly less than in control dogs 
(P c 0.01; Table 1). The arterial plasma NE response to 
hypoglycemia was suppressed (P < 0.05 vs. control dogs) 
but not eliminated (A = +200 t 60 pg/ml, P c 0.025) in 
the hexamethonium-treated dogs (Table 2). 
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Table 3. Plasma NE and pancreatic NE output before and during hypoglycemia 
Treatment n 
NEFA 
p&z/ml BF SI’DV, NE Output, 
NE ml/min SI’I)V pg/min 
Control dogs 
Baseline 
During insulin-induced hypoglycemia 
APancreatic NE output 
SS infused 
Baseline 
During insulin-induced hypoglycemia 
APancreatic NE output 
Post-SS 
APancreatic NE output 
Hexamethonium 
Baseline 
During insulin-induced hypoglycemia 
APancreatic NE output 
Spinal cord transection 
Baseline 
During insulin-induced hypoglycemia 
APancreatic NE output 
9 
170t30 
740t90 
13ot,20 
24Ozk20 
ll.lH.6 
8.4t1.3 
54Od40 
56OklOO 
+20t130 
11 
160t20 
560tllO 
110tlO 
240t40 
12.2tl.O 
11.6tl.l 
420t250 
89Ok150 
+470* 150* 
1,380f310 
+970+28Oj- 
77Ok220 37ost90 13.3t1.6 
6 
1 lOt40 
31Ok70 
1 lot60 
300t80 
5.7kO.4 
5.OkO.6 
310*140 
770t260 
+460*170$ 
6 
30t10 
3OklO 
4OklO 9.5t1.2 
3OIklO 8.2kl.O 
19Ok70 
130t40 
-70250 
Values are means k SE, at 45-60 min postinsulin injection, except post-SS values that are 65-75 min postinsulin. FA, femoral artery; SPDV, 
superior pancreaticoduodenal vein; BF, blood flow. * P c 0.01. “r P c 0.005. $ P < 0.025. 
Table 4. Plasma and pancreatic GLIR output before and during hypoglycemia 
P&-n1 BF SPIlV, GLIR Output, 
ml/min Pdml 
Treatment t-l 
GLIRFA GLIRsm 
Control dogs 
Baseline 
During insulin-induced hypoglycemia 
APancreatic GLIR output 
SS infused 
Baseline 
During insulin-induced hypoglycemia 
APancreatic GLIR output 
During insulin-induced hypoglycemia, post-SS 
APancreatic GLIR output 
Hexamethonium 
Baseline 
During insulin-induced hypoglycemia 
APancreatic GLIR output 
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Baseline 
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APancreatic GLIR output 
9 
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6 
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Values are means t SE at 45-60 min postinsulin injection, except post-SS values that are 65-75 min postinsulin. GLIR, galanin-like 
immunoreactivity. * P < 0.025. t P < 0.01. 
Pancreatic NE output was increased significantly dur- 
ing hypoglycemia in the hexamethonium-treated dogs 
(A = +510 t 170 pg/min, P < 0.025; Fig. 3A and Table 3). 
There was also a significant increase of pancreatic GLIR 
output during hypoglycemia in these animals (A = +I10 
t 30 fmol/min, P < 0.01; Fig. 3B and Table 4). 
Arterial glucose, glucagon, and NE and pancreatic NE 
and GLIR output responses after insulin injection in dogs 
with cervical spinal cord section. Plasma glucose in cord- 
sectioned dogs (n = 6) decreased to 15 t 3 mg/dl at 45-60 
min postinsulin (P < 0.01 vs. control dogs; Table 1) with 
a nadir of 12 t 2 mg/dl at 60 min. The decrement was -76 
t 8 mg/dl. Arterial plasma glucagon did not increase 
significantly during hypoglycemia (A = +5 t 7 pg/ml); 
this response was significantly less than that in control 
dogs (P < 0.01; Table 1). Arterial plasma NE also did not 
change in these animals averaging 30 t 10 pg/ml before 
and 30 t 10 pg/ml 45-60 min after insulin injection 
(P < 0.05 vs. control dogs; Table 2). 
Pancreatic NE output did not increase in these animals 
during the hypoglycemic period (A = -70 t 50 pg/min; 
Fig. 4A and Table 3). Similarly, pancreatic GLIR output 
did not increase significantly during hypoglycemia in 
cord-sectioned dogs (A = +80 t 50 fmol/min; Figure 4B, 
and Table 4). 
Correlation of changes of pancreatic NE and GLIR 
output. The mean changes of NE output in control dogs, 
in S&treated dogs (both during and immediately after 
the SS infusion was discontinued), in hexamethonium- 
treated dogs, and in cord-sectioned dogs were signifi- 
cantly correlated with the corresponding mean changes of 
GLIR output (r = 0.8557, P < 0.025, n = 5). 
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Fig. 2. Pancreatic output of NE and GLIR before, during 
insulin -induced hypoglycemia in 11 experiments conducted 
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Fig. 3. Pancreatic output of NE and GLIR before, during, and 
after insulin-induced hypoglycemia in 6 experiments conducted in dogs 
pretreated with hexamethonium. 
DISCUSSION 
Recent experimental evidence suggests that the neu- 
ropeptide galanin may be a sympathetic neurotransmitter 
in the endocrine pancreas. Galanin is present in sympa- 
thetic nerves innervating the endocrine pancreas (1, 38, 
46) and is released with NE during electrical activation of 
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Fig. 4. Pancreatic output of NE and GLIR before, during, and after 
insulin-induced hypoglycemia in 6 experiments conducted in dogs with 
spinal cord transection. 
these sympathetic nerves (21, 23). Because combined CY- 
and P-adrenergic antagonists do not block all of the 
effects of electrical sympathetic nerve stimulation on 
pancreatic hormone secretion (9, 20, 37), the effects of 
sympathetic nerve activation on pancreatic islet func- 
tion, which are not adrenergically mediated, could be me- 
diated by galanin (4, 22). 
Despite this evidence, there has been no demonstration 
that galanin is in fact coreleased with NE from the pan- 
creas during endogenous reflex activation of pancreatic 
sympathetic nerves that occurs during certain types of 
stress (30). There is evidence to suggest that another 
neuropeptide, neuropeptide Y, may not be coreleased 
with NE in significant quantities during low-intensity 
neural activation (39,45). Because endogenous nerve im- 
pulses that would occur during reflex neural activation 
are low-frequency potentials, it was important to deter- 
mine whether galanin is coreleased with NE during the 
presumably low-intensity reflex activation of the sympa- 
thetic nervous system that might occur during stress. In 
a previous study, we demonstrated that central neuroglu- 
copenic stress induced by administration of 2-deoxy-D- 
glucose activates the noradrenergic nerves innervating 
the pancreas (30). Therefore we chose the similar, but 
reversible, stress of insulin-induced hypoglycemia to 
activate pancreatic sympathetic nerves in halothane- 
anesthetized dogs. 
In the first experiment (control dogs), insulin injection 
lowered the plasma glucose to a mean of 34 + 3 mg/dl, yet 
neither pancreatic NE nor GLIR spillover increased. Be- 
cause the administration of a large dose of 2-deoxy-D- 
glucose clearly increased pancreatic NE spillover in pre- 
vious experiments (30), we hypothesized that more severe 
hypoglycemia might be necessary to activate pancreatic 
sympathetic nerves. However, we had observed that even 
high doses of insulin did not lower plasma glucose below 
30 mg/dl in the control dogs. Therefore we infused SS to 
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block the counterregulatory glucagon response to hy- 
poglycemia, which allowed the plasma glucose to fall to 
15 mg/dl after insulin injection (32). During this severe 
hypoglycemia, pancreatic NE output was significantly in- 
creased 50-60 min after insulin injection. Pancreatic 
GLIR output did not increase significantly at this time, 
suggesting either that the change of galanin output was 
too small to be measured reliably or that pancreatic gala- 
nin was not coreleased with NE. Therefore corelease of 
NE and GLIR was not demonstrated at these time points. 
However, after the SS infusion was discontinued, pancre- 
atic GLIR output did increase significantly, and NE out- 
put increased further, suggesting that NE and GLIR were 
coreleased. 
To confirm NE and galanin corelease during severe 
hypoglycemia, a second independent approach was used 
to produce severe hypoglycemia. Data from previous ex- 
periments demonstrated that submaximal doses of the 
ganglionic antagonist hexamethonium were sufficient to 
reduce the autonomically mediated glucagon response 
during insulin-induced hypoglycemia, resulting in plasma 
glucose nadirs equivalent to those in SS-infused and cord- 
sectioned animals (3 1). This degree of ganglionic block- 
ade reduced, but did not abolish, the arterial NE response 
to hypoglycemia, demonstrating only a partial impair- 
ment of whole body sympathetic neural activation, sug- 
gesting that it might allow activation of pancreatic sym- 
pathetic nerves. Indeed, in the hexamethonium-treated 
dogs, there were significant increases of both pancreatic 
NE and GLIR output. 
To determine whether the increases of pancreatic NE 
and GLIR output were due to a centrally mediated in- 
crease of sympathetic outflow to the pancreas, rather 
than to an effect of low glucose levels directly on pancre- 
atic sympathetic nerve terminals, as suggested by certain 
in vitro studies (15,35), severe hypoglycemia was induced 
in dogs in which the cervical spinal cord was surgically 
transected. This procedure interrupts the sympathetic 
neural pathway from the brain to the pancreas and adre- 
nal medulla, impairs counterregulatory increases of glu- 
cagon (33) and plasma catecholamines during hypoglyce- 
mia, and thereby allows plasma glucose to fall to levels 
comparable with the SS-infused and hexamethonium- 
treated dogs (31). No significant increase of either pan- 
creatic NE or GLIR occurred in these animals, despite 
the presence of severe hypoglycemia, suggesting that in- 
creased sympathetic neurotransmitter release from the 
pancreas in vivo is centrally mediated. This conclusion is 
consistent with the demonstration that the increase of 
pancreatic NE spillover induced by 2-deoxy-D-glucose ad- 
ministration is markedly impaired by surgical pancreatic 
denervation (30). 
Although both the SS-infused and hexamethonium- 
treated animals exhibited reflex release of pancreatic 
galanin with NE, these agents appear to inhibit the neu- 
ral activation. In the SS-treated animals, there was an 
increase of both pancreatic NE and GLIR output when 
the SS infusion was discontinued, suggesting that the SS 
had been restraining pancreatic NE and GLIR output. 
SS is well known to directly inhibit the release of 
numerous hormones, but there are few reports of an 
inhibitory effect of SS on neurotransmitter release (27). 
Alternatively, SS may have restrained pancreatic sympa- 
thetic neurotransmitter release via a central action, since 
central administration of SS analogues can inhibit in- 
creases of plasma catecholamines induced by a variety 
of stresses, including insulin-induced hypoglycemia or 
2-deoxy-D-glucose administration (12, 13, 25). Although 
there was not a significant suppression of the arterial NE 
response to hypoglycemia in the SS-infused dogs com- 
pared with controls, a larger response would have been 
expected, since the glucose nadir was significantly lower 
in these animals. Thus SS may have produced a relative 
inhibition of general noradrenergic outflow during 
hypoglycemia. In the case of hexamethonium, partial in- 
hibition was expected because this nicotinic antagonist 
impairs neural transmission in sympathetic ganglia (56). 
Indeed, the arterial NE response was approximately one- 
third of that in the control animals, despite more severe 
hypoglycemia. Despite the limitations of the pharmaco- 
logical interventions, these experiments were able to pro- 
vide evidence for the corelease of galanin with NE during 
reflex activation of the pancreatic sympathetic nerves. 
Additional support for corelease of galanin with NE is 
provided by the correlation of the increments of pancre- 
atic NE output with galanin output across the four 
studies. This finding is consistent with the demonstra- 
tion that both NE and GLIR are released during intense 
electrical stimulation of the sympathetic nerves innervat- 
ing the dog pancreas (21, 23) and with the results of 
immunostaining experiments that found that GLIR is 
colocalized with tyrosine hydroxylase in some, but not all, 
noradrenergic nerve fibers in the canine pancreas (1). 
Although it has long been hypothesized that the sym- 
pathetic innervation of the pancreas is involved in the 
changes of insulin and glucagon secretion observed during 
systemic stress (8, 34, 43, 47), this hypothesis has been 
primarily based on indirect evidence. For example, elec- 
trical stimulation of the sympathetic nerves to the pan- 
creas inhibits insulin secretion (20, 47) and stimulates 
glucagon secretion (20,40). However, it has only recently 
been established that the sympathetic noradrenergic in- 
put to the pancreas is activated during systemic stress 
(30). If neuronally released galanin does in fact function 
along with NE as a sympathetic neurotransmitter in the 
pancreas, then increased pancreatic galanin release dur- 
ing hypoglycemia could inhibit insulin, stimulate gluca- 
gon secretion, and thereby increase hepatic glucose 
production ( 14). 
However, one must be cautious when postulating a 
physiological role for pancreatic galanin, or pancreatic 
NE for that matter, in hypoglycemic counterregulation. 
First, a definitive role for the direct sympathetic inner- 
vation of the pancreas in mediating islet hormone re- 
sponses has not been demonstrated. Second, the NE and 
GLIR output measured in the present study was from the 
entire right lobe of the dog pancreas and the proximal 
duodenum, not solely from pancreatic endocrine tissue. 
Therefore, these measurements do not necessarily reflect 
increased noradrenergic and galaninergic input to the is- 
lets during hypoglycemia. However, histological studies 
indicate that the islets receive a preponderance of the 
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galaninergic innervation of the pancreas (1). Finally, se- 
vere hypoglycemia was required to activate the nor- 
adrenergic and galaninergic nerves to the pancreas in 
these anesthetized acutely laparotomized animals. Thus 
Epi and glucagon, which are secreted well before this 
severe level of hypoglycemia is reached, may be more 
important than pancreatic sympathetic nerves for early 
glucose counterregulation. Therefore, under the condi- 
tions of these experiments, NE and galanin could only be 
involved in hypoglycemic counterregulation during severe 
hypoglycemia. However, it is possible that, in the absence 
of anesthesia and surgery, activation of pancreatic nora- 
drenergic and galaninergic nerves may occur during less 
severe hypoglycemia. Further experiments in chronically 
catheterized conscious animals would be necessary to ad- 
dress this possibility. 
In summary, pancreatic GLIR and NE output increase 
during severe insulin-induced hypoglycemia in hal- 
othane-anesthetized laparotomized dogs, demonstrating 
that endogenous reflex activation of pancreatic sympa- 
thetic nerves can result in corelease of both a peptidergic 
and classical neurotransmitter. Because these pancreatic 
neural responses are abolished by spinal cord transection, 
they appear to be centrally mediated. Although a defini- 
tive physiological role for the pancreatic sympathetic 
nerves remains to be established, the increased release of 
neuronal NE and galanin could contribute to the coun- 
terregulatory changes of islet function for defending 
plasma glucose during severe hypoglycemia (16, 26). 
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